We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
They show as zero value in my Halifax account. Getting ****ed of about lack of info.
Luckiest decision of the last 12 months for me was selling my bitcoin (originally investment $10 - sold it at £5600) and putting it into TILS a couple of weeks ago at 100.45p. Won't have a fluke that good again haha.
Sorry LBC just on my bros level 2. Shiraz
V glad to hear it :). Got a friend stuck on £2.30
So hope he can be in same position soon iA (god willing). I derisked at £1.40 lol. That was a clever move lol
Shiraz, I'm very very happy to report I'm out of the 300k loss club and finally in BLUE yabadabadooooooooooooooo
Was a tough time but I survived to tell the Lazarus story haha
people seem to think if they do not appear in their accounts, even with zero current value, they won't get them. If you are entitled to them you WILL receive them when they are listed. When will that be? No one knows yet!
Ive been ok since the 130’s but glad for LTH like my good friend LBC, spinnaker etc. Hopefully finally in the blue and you got accustem. See tils isnt that bad lol
Cannot agree enough!!
I have some showing in my HL account.
I have none showing in my T212 account.
Doesn't matter either way until they have value and are tradeable. Nobody knows when this will happen so its a case of sitting and waiting, just like with most shares.
We will get shares when the company launches an IPO and not before as previously stated this has been covered numerous times.no one is going to miss out if you held share on record date
Simple way for that to happen is for the company to give the information.
You will only get the shares when they are listed. Moving TILS to main market is NOT the same as listing ACCUSTEM.
Change the record ,this has been donr to death
Like many Brokers, AJ Bell have said they will credit accounts when they become trade-able, so when they are listed.
Think most of us are still waiting. I have e mailed Share Centre again as I have real concerns that when they go to interactive investor next month, if not recorder then we might have a battle to prove entitlement so am looking for a letter or e mail of confirmation.
So am I.
Anyone still waiting for their demerger shares?
I am. My broker is ajbell.
Alastair.. great write up... shows the potential is great.. I think success in this trial will de risk much of the rest of our portfolio also. It is time for solid results now or nasdaq will take us to the cleaners. Very excited but also quite nervous at the moment. Im sure many other LTH feel the same.
190/193
If the delivery method works for Covid then that is simply enormous for pharma. it is clear TILS are chasing the biggest markets - if the tech works the resultant value is staggering. There are atleast 5 NDA's and trials with third parties - no doubt the pharma industry is very excited about what TILS have.
Looking v strong. Looks like we’re heading up. Great volume too early doors
The fact is we are well known to big pharma. Kunwar regular talks of big pharma and with ‘several ndas’ with them so far for our blockbuster drugs, we can expect heavy newsflow up to Q2 2021 Phase II trials commencing and if they go well then expect big names to be circling.
The covid story has legs. Sanofi/Regeneron (who have we just employed!!!!) and Roche have all hit difficulties with their drugs which makes TZLS 501 a candidate for therapeutic work and especially with our patent for oral and nasal delivery applicable to remdesivir, TILS are well placed to work with these groups. Any sniff of big pharma involvement will set this share price alight.
TILS have patents on oral and nasal formulation which is important as some diseases will be easier to target/respond better if given in different manners. Either way this is far superior to the high toxicity and high cost attributed to intravenous delivery. The IP has been developed with Dr Howard Weiner, sits on the TILs board, who runs the Ann Romney Center at Harvard and is one of the top 5 minds on MS globally ie when he speaks people listen.
Focussing on the two sectors that TILS have identified in conjunction with big pharma. These phase 2 trials start in July 2020 with results in Q2 2021.
Crohns – our CDA partner on this indication have said they want to Phase II orally administered Foralumab– worth $3.8bn in 2016 and anticipated to be $4.7bn by 2025 – major players in the treatment include Abbvie, Pfizer, J&J, Allergan.
MS – our CDA partner have said they want to Phase II nasally administered Foralumab - worth $20.83bn in 2019 and the drugs are high cost and are lifelong as there is no cure. Novartis, Sanofi, Roche, Merck, Pfizer. There have been major corporate moves in this sector in recent years – Receptos invented Ozanimod which was approved in March 2020 for MS and Receptos were taken over by Celgene for $7.2bn in 2015 (Celgene then were taken over by Bristol Myers Squibb for $74bn largest ever TO in pharma). This shows that big pharma is willing to take a long view and acquire early if the early trials are positive.
It has also been discovered that Foralumab could work in the Alzheimers market (£17.7bn per annum and a growth rate of 12.3% annual.
TILS amongst their 256 patents have a patent for the oral/nasal administration of Foralumab which is transformational for the sector.
"The issuance of this first-ever patent on formulation for oral administration of mAbs is a very exciting and timely development, as it facilitates a transformational avenue for immunotherapies" commented Dr. Howard L. Weiner, Chairman of Tiziana's Scientific Advisory Board
I have written a short piece on why foralumab in conjunction with our delivery technology and patent is the 'crown jewel' in TILS, our current value will be truly dwarfed by Foralumab.
Foralumab is the only fully human (as opposed to humanised which comes from mice thus making it easier to get approved on and means that humans produce less immune response to it so it works better) anti CD3 (attaches to t cells as part of the immune system) monoclonal antibody in clinical development anywhere in the world. Historically Anti CD3 have led to greater toxicities which has been a problem, TILS have the solution and this has been through a safety trial with no issues) It has potential to be used in autoimmune and inflammatory diseases including Crohns, MS, type 1 diabetes ($25bn annual market), Inflammatory bowel disease ($15.9bn annual market), psoriasis and arthritis ($8.6bn annual market), CV19.
GC calls foralumab the tiziana ‘crown jewel’ as it targets the largest markets in pharma. GC talks of Roche and Biogene having blockbuster drugs in the MS field. Foralumab is a monoclonal antibody a class of drugs which has been shown to be the greatest revenue generator in pharma full stop. 7 of the top 10 biggest revenue generators in pharma in 2019 were monoclonal antibodies and monoclonal antibodies in 2019 generated $122bn in turnover and by 2024 this is estimated to exceed $200bn a year. These drugs are given intravenously ie they get put into the body in a non targeted way but TILS have a patent and the technology to deliver orally, nasally and in lung which reduces toxicity and is more targeted. Apply that tech to a $100bn+ market a year and you have a major, major breakthrough with TILS leading it alongside what GC reckons are multi billon dollar a year turnovers for our targets if successful.
Hear hear. Company is good enough on its own merits. Just blocks up the genuinely good posts.
I'm thinking any RNS would be at 2.30pm to allow both markets to receive update at the same time. Also, perhaps wrongly, assuming it will be early next week, given Milciclib fireside today...? That PR push would get lost if the Brazil top line data was published (assuming it's positive)...